Recommendations for mid-adult HPV vaccination
Work Group considerations

Lauri Markowitz, MD
Division of Viral Diseases
Advisory Committee on Immunization Practices
February 27, 2019
Current recommendations for HPV vaccination in the United States

- **Routine vaccination**
  - Age 11 or 12 years
  - Vaccination can be started at age 9 years

- **Catch-up vaccination**
  - Females through age 26 years
  - Males through age 21 years
  - Certain populations through age 26 years*

- **Males aged 22 through 26 years may be vaccinated**

*Men who have sex with men, transgender persons, and persons with certain immunocompromising conditions

MMWR 2014;63 (RR05)  MMWR 2015;64:300-4  MMWR 2016; 65:2105-8
Work Group considerations

- The Work Group is still reviewing results from health economic analyses as well as other data related to this policy question
- Several different policy options have been discussed
Mid-adult vaccination: Work Group discussions

Majority opinion

- **Routine vaccination**
  - No change: age 11 or 12 years; vaccination can be started at age 9 years

- **Catch-up vaccination**
  - Harmonization of upper age for catch-up: females and males
  - Could be the current age or another age (e.g., 26 or 30 years)

- **For persons older than the catch-up age**
  - *Individual decision making* through age 45 years
Mid-adult vaccination: Work Group discussions
Minority opinion

- **Routine vaccination**
  - No change: age 11 or 12 years; vaccination can be started at age 9 years

- **Catch-up vaccination**
  - Harmonization of upper age for catch-up: females and males
  - Could be the current age or another age (e.g., 26 or 30 years)

- **For persons older than the catch-up age**
  - *Individual decision making through age 45 years*
  - No recommendation
Concerns among Work Group members favoring no recommendation

Minority opinion

- Few benefits for vaccination in the older age group
- Diversion of focus from adolescent program
- Potential harms to the HPV vaccination program due to temporally associated adverse events in this age group
- Global HPV vaccine shortage
Mid-adult vaccination: Work Group discussions

- No Work Group members in favor of a catch-up recommendation through age 45 years
If *Individual Decision Making* recommended in some age groups

- What guidance to provide?
- How to communicate who might benefit?
- How to communicate the lower effectiveness in this age group?
Next steps for ACIP HPV Vaccines Work Group

- Continue to review results from health economic modeling and other related data
- Complete Evidence to Recommendations Framework
- Prepare for a vote in June 2019
ACIP HPV Vaccines
Work Group

ACIP Members
Peter Szilagyi (Chair)
Jose Romero
Kevin Ault

Ex Officio Members
Jeff Roberts (FDA)
Joohee Lee (FDA)

CDC Lead
Lauri Markowitz

Liaison Representatives
Shelley Deeks (NACCI)
Linda Eckert (ACOG)
Sandra Fryhofer (ACP)
Amy Middleman (SAHM)
Chris Nyquisto (AAP)
Sean O’Leary (PIDS)
Robin O’Meara (AAFP)
Patricia Whitley-Williams (NMA)
Jane Zucker (AIM)

Consultants
Joseph Bocchini
Tamera Coyne-Beasley
John Douglas
Allison Kempe
Aimee Kreimer (NCI)
Debbie Saslow (ACS)
Rodney Willoughby
Rachel Winer

CDC Contributors
Harrell Chesson
Julianne Gee
Elissa Meites
Jeanne Santoli
Mona Saraiya
John Su
Shannon Stokley
Lakshmi Panagiotakoukos
Elizabeth Unger
Charnetta Williams
For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.